生命科学资讯
生物技术与制药领域的最新动态
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FDA explains how some copycat drugs can still win three years of exclusivity
安捷伦科技（A）分析师评级更新：摩根士丹利维持L评级 - GuruFocus
Agilent Technologies (A) Analyst Rating Update: Morgan Stanley L - GuruFocus
[144] 赛默飞世尔科技公司提交美国证券交易委员会文件 - 股票巨头
[144] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan
Kyowa Kirin abandons touted eczema drug following safety review
摩根士丹利将安捷伦科技（NYSE:A）目标价下调至160美元 - MarketBeat
Morgan Stanley Lowers Agilent Technologies (NYSE:A) Price Target to $160.00 - MarketBeat
GSK nabs two Frontier Biotech siRNA assets in $1B deal
Wave of deals lifts large-cap biopharma stocks
US taking a closer look at China biotech subsidies
Systimmune’s iza-bren hits phase III breast cancer goals in China
Returning to pulmonary hypertension, GSK buys 35Pharma
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
Biohaven因研发管线进展顺利，缩减裁员规模。
Biohaven reduces scope of R&D cutbacks as pipeline progresses
MindMaze寻求"战略替代方案"，瞄准美国市场扩张，两名董事会成员离职。
MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
Disc公司裁员20%以稳定运营，此前FDA罕见病药物遭拒。
Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
Thermo Fisher在Raymond James会议上的战略增长洞见 - Investing.com
Thermo Fisher at Raymond James Conference: Strategic Growth Insights - Investing.com